Article
A robust mRNA signature obtained via Recursive Ensemble Feature Selection predicts the responsiveness of omalizumab in moderate-to-severe asthma
2022-10-24
Abstract excerpt
<h4>Background: </h4> : Not being well controlled by therapy with inhaled corticosteroids and long-acting β2 agonist bronchodilators is a major concern for severe-asthma patients. Current treatment option for these patients is the use of biologicals such as anti-IgE treatment, omalizumab, as add-on therapy. Despite the accepted use of omalizumab, patients do not always benefit from it. Therefore, there is a need t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bfd67346-92d5-51df-aab3-0553e5a2ba37
- DOI
- 10.22541/au.166663264.45554320/v1
